Anticoagulation	B:C0003281
for	O
stroke	O
prevention	I:C1277289
in	O
elderly	O
patients	O
with	O
non-valvular	O
atrial	O
fibrillation	I:C0004238
:	O
what	O
are	O
the	O
obstacles	O
?	O

Anticoagulation	O
for	O
stroke	B:C1277289
prevention	I:C1277289
in	O
elderly	O
patients	O
with	O
non-valvular	O
atrial	O
fibrillation	I:C0004238
:	O
what	O
are	O
the	O
obstacles	O
?	O

Anticoagulation	O
for	O
stroke	O
prevention	I:C1277289
in	O
elderly	B:C0001792
patients	O
with	O
non-valvular	O
atrial	O
fibrillation	I:C0004238
:	O
what	O
are	O
the	O
obstacles	O
?	O

Anticoagulation	O
for	O
stroke	O
prevention	I:C1277289
in	O
elderly	O
patients	O
with	O
non-valvular	B:C0243095
atrial	O
fibrillation	I:C0004238
:	O
what	O
are	O
the	O
obstacles	O
?	O

Anticoagulation	O
for	O
stroke	O
prevention	I:C1277289
in	O
elderly	O
patients	O
with	O
non-valvular	O
atrial	B:C0004238
fibrillation	I:C0004238
:	O
what	O
are	O
the	O
obstacles	O
?	O

The	O
elderly	B:C0001792
with	O
atrial	O
fibrillation	I:C0004238
are	O
more	O
prone	O
to	O
stroke	O
.	O

The	O
elderly	O
with	O
atrial	B:C0004238
fibrillation	I:C0004238
are	O
more	O
prone	O
to	O
stroke	O
.	O

The	O
elderly	O
with	O
atrial	O
fibrillation	I:C0004238
are	O
more	O
prone	O
to	O
stroke	B:C0038454
.	O

Oral	B:C0354604
anticoagulants	I:C0354604
such	O
as	O
warfarin	O
are	O
effective	O
in	O
the	O
prevention	O
of	O
atrial	O
fibrillation	I:C0004238
-	O
associated	O
stroke	O
and	O
systemic	O
embolism	O
.	O

Oral	O
anticoagulants	I:C0354604
such	O
as	O
warfarin	B:C0043031
are	O
effective	O
in	O
the	O
prevention	O
of	O
atrial	O
fibrillation	I:C0004238
-	O
associated	O
stroke	O
and	O
systemic	O
embolism	O
.	O

Oral	O
anticoagulants	I:C0354604
such	O
as	O
warfarin	O
are	O
effective	O
in	O
the	O
prevention	B:C0199176
of	O
atrial	O
fibrillation	I:C0004238
-	O
associated	O
stroke	O
and	O
systemic	O
embolism	O
.	O

Oral	O
anticoagulants	I:C0354604
such	O
as	O
warfarin	O
are	O
effective	O
in	O
the	O
prevention	O
of	O
atrial	B:C0004238
fibrillation	I:C0004238
-	O
associated	O
stroke	O
and	O
systemic	O
embolism	O
.	O

Oral	O
anticoagulants	I:C0354604
such	O
as	O
warfarin	O
are	O
effective	O
in	O
the	O
prevention	O
of	O
atrial	O
fibrillation	I:C0004238
-	O
associated	O
stroke	B:C0038454
and	O
systemic	O
embolism	O
.	O

The	O
CHADS2	B:C2585876
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	B:C4049268
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	B:C3875442
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	B:C0038454
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	B:C0035648
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	B:C0004238
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	B:C0004238
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	O
anticoagulant	I:C0354604
.	O

The	O
CHADS2	O
or	O
CHA2D2	O
-	I:C4049268
VASc	I:C4049268
score	I:C4049268
and	O
HAS	O
-	I:C3875442
BLED	I:C3875442
score	I:C3875442
were	O
developed	O
to	O
stratify	O
stroke	O
risk	O
associated	O
with	O
atrial	O
fibrillation	I:C0004238
and	O
bleeding	O
risk	O
in	O
a	O
patient	O
with	O
atrial	O
fibrillation	I:C0004238
,	O
respectively	O
,	O
to	O
facilitate	O
the	O
decision	O
for	O
and	O
safe	O
use	O
of	O
oral	B:C0354604
anticoagulant	I:C0354604
.	O

Nonetheless	O
,	O
the	O
decision	O
for	O
anticoagulation	B:C0003281
is	O
not	O
straightforward	O
and	O
the	O
elderly	O
with	O
non-valvular	O
atrial	I:C0004238
fibrillation	I:C0004238
are	O
often	O
precluded	O
from	O
anticoagulant	O
prescription	I:C0199242
.	O

Nonetheless	O
,	O
the	O
decision	O
for	O
anticoagulation	O
is	O
not	O
straightforward	O
and	O
the	O
elderly	B:C0001792
with	O
non-valvular	O
atrial	I:C0004238
fibrillation	I:C0004238
are	O
often	O
precluded	O
from	O
anticoagulant	O
prescription	I:C0199242
.	O

Nonetheless	O
,	O
the	O
decision	O
for	O
anticoagulation	O
is	O
not	O
straightforward	O
and	O
the	O
elderly	O
with	O
non-valvular	B:C0004238
atrial	I:C0004238
fibrillation	I:C0004238
are	O
often	O
precluded	O
from	O
anticoagulant	O
prescription	I:C0199242
.	O

Nonetheless	O
,	O
the	O
decision	O
for	O
anticoagulation	O
is	O
not	O
straightforward	O
and	O
the	O
elderly	O
with	O
non-valvular	O
atrial	I:C0004238
fibrillation	I:C0004238
are	O
often	O
precluded	O
from	O
anticoagulant	B:C0199242
prescription	I:C0199242
.	O

Advanced	O
age	O
and	O
disadvantages	O
associated	O
with	O
the	O
elderly	B:C0001792
such	O
as	O
fall	O
,	O
comorbidities	O
,	O
cognitive	O
impairment	I:C0338656
,	O
and	O
polypharmacy	O
contribute	O
to	O
the	O
over	O
-	O
concern	O
of	O
physicians	O
about	O
bleeding	O
risk	O
.	O

Advanced	O
age	O
and	O
disadvantages	O
associated	O
with	O
the	O
elderly	O
such	O
as	O
fall	B:C0085639
,	O
comorbidities	O
,	O
cognitive	O
impairment	I:C0338656
,	O
and	O
polypharmacy	O
contribute	O
to	O
the	O
over	O
-	O
concern	O
of	O
physicians	O
about	O
bleeding	O
risk	O
.	O

Advanced	O
age	O
and	O
disadvantages	O
associated	O
with	O
the	O
elderly	O
such	O
as	O
fall	O
,	O
comorbidities	O
,	O
cognitive	B:C0338656
impairment	I:C0338656
,	O
and	O
polypharmacy	O
contribute	O
to	O
the	O
over	O
-	O
concern	O
of	O
physicians	O
about	O
bleeding	O
risk	O
.	O

Advanced	O
age	O
and	O
disadvantages	O
associated	O
with	O
the	O
elderly	O
such	O
as	O
fall	O
,	O
comorbidities	O
,	O
cognitive	O
impairment	I:C0338656
,	O
and	O
polypharmacy	B:C2922974
contribute	O
to	O
the	O
over	O
-	O
concern	O
of	O
physicians	O
about	O
bleeding	O
risk	O
.	O

Advanced	O
age	O
and	O
disadvantages	O
associated	O
with	O
the	O
elderly	O
such	O
as	O
fall	O
,	O
comorbidities	O
,	O
cognitive	O
impairment	I:C0338656
,	O
and	O
polypharmacy	O
contribute	O
to	O
the	O
over	O
-	O
concern	O
of	O
physicians	B:C0031831
about	O
bleeding	O
risk	O
.	O

Various	O
treatment	B:C0087111
options	O
such	O
as	O
low	O
-	O
intensity	O
warfarin	O
and	O
aspirin	O
plus	O
clopidogrel	O
have	O
been	O
suggested	O
but	O
are	O
inferior	O
to	O
dose	O
-	O
adjusted	O
warfarin	O
.	O

Various	O
treatment	O
options	O
such	O
as	O
low	O
-	O
intensity	O
warfarin	B:C0043031
and	O
aspirin	O
plus	O
clopidogrel	O
have	O
been	O
suggested	O
but	O
are	O
inferior	O
to	O
dose	O
-	O
adjusted	O
warfarin	O
.	O

Various	O
treatment	O
options	O
such	O
as	O
low	O
-	O
intensity	O
warfarin	O
and	O
aspirin	B:C0004057
plus	O
clopidogrel	O
have	O
been	O
suggested	O
but	O
are	O
inferior	O
to	O
dose	O
-	O
adjusted	O
warfarin	O
.	O

Various	O
treatment	O
options	O
such	O
as	O
low	O
-	O
intensity	O
warfarin	O
and	O
aspirin	O
plus	O
clopidogrel	O
have	O
been	O
suggested	O
but	O
are	O
inferior	B:C0542339
to	O
dose	O
-	O
adjusted	O
warfarin	O
.	O

Various	O
treatment	O
options	O
such	O
as	O
low	O
-	O
intensity	O
warfarin	O
and	O
aspirin	O
plus	O
clopidogrel	O
have	O
been	O
suggested	O
but	O
are	O
inferior	O
to	O
dose	O
-	O
adjusted	O
warfarin	B:C0043031
.	O

Novel	O
oral	B:C0354604
anticoagulants	I:C0354604
with	O
promising	O
efficacy	O
and	O
convenience	O
hold	O
great	O
appeal	O
.	O

Optimal	O
management	O
of	O
underlying	O
medical	O
conditions	O
and	O
modifiable	O
stroke	B:C0038454
risk	O
factors	I:C0035648
,	O
together	O
with	O
intervention	O
to	O
improve	O
the	O
safe	O
use	O
of	O
oral	O
anticoagulants	I:C0354604
,	O
are	O
useful	O
.	O

Optimal	O
management	O
of	O
underlying	O
medical	O
conditions	O
and	O
modifiable	O
stroke	O
risk	B:C0035648
factors	I:C0035648
,	O
together	O
with	O
intervention	O
to	O
improve	O
the	O
safe	O
use	O
of	O
oral	O
anticoagulants	I:C0354604
,	O
are	O
useful	O
.	O

Optimal	O
management	O
of	O
underlying	O
medical	O
conditions	O
and	O
modifiable	O
stroke	O
risk	O
factors	I:C0035648
,	O
together	O
with	O
intervention	B:C0184661
to	O
improve	O
the	O
safe	O
use	O
of	O
oral	O
anticoagulants	I:C0354604
,	O
are	O
useful	O
.	O

Optimal	O
management	O
of	O
underlying	O
medical	O
conditions	O
and	O
modifiable	O
stroke	O
risk	O
factors	I:C0035648
,	O
together	O
with	O
intervention	O
to	O
improve	O
the	O
safe	O
use	O
of	O
oral	B:C0354604
anticoagulants	I:C0354604
,	O
are	O
useful	O
.	O

